[
    "s, 1H), 7.43 (s, 1H), 6.39 (t, J= 54 Hz, 1H), 3.82 (s, 3H), 3.51 - 3.18 (m, 5H), 2.98 - 2.62 (m, 2H), 2.12 - 1.92 (m, 2H), 1.65- 1.55 (m, 2H). </p> [0934] Step 4: l-{[l-(2,2-difluoroethyl)piperidin-4-yl](l-methyI-lH-pyrazol-4- yl)sulfamoyl}-3-(l,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea sodium salt. General procedure B was followed using {[(l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]amino}sulfonyl chloride \n\n and l-(2,2-difluoroethyl)-N-(l- methylpyrazol-4-yl)piperidin-4-amine trifluoroacetate. The crude product was purified by prep-HPLC (column: Nano-Micro Unisil 8-120 C18 Ultra Plus 250x50 mm; mobile phase: [water (10 mM NH4HCO3) - ACN]; B: 3 - 33 %, 20 min) to give the title compound as a white solid (Y = 8 %). *H NMR (400 MHz, methanol-c 4) d ppm 7.71 (s, 1H), 7.42 (s, 1H), 6.98 (s, 1H), 6.03 - 5.73 (m, 1H), 4.19 - 4.01 (m, 1H), 3.89 (s, 3H), 3.00 - 2.92 (m, 2H), 2.88 (t, J= 7 Hz, 4H), 2.79 (t, j= 7 Hz, 4H), 2.72 - 2.62 (m, 2H), 2.32 (t, /= 12 Hz, 2H), 2.13 - 2.02 (m, 4H), 1.95 - 1.85 (m, 2H), 1.56 - 1.40 (m, 2H). LC-MS (ESI): m/z: [M+H]<sup>+</sup> = 523.2 </p>Example 46. 3-(l,2,3,5,6,7-hexahydro-s-indacen-4-yl)-l-[(l-methyl-lH-pyrazoI-4-yI)[2- (morpholin-4-yI)ethyl] sulfamoyl] urea sodium salt </p></p> [0935] Step 1: l-methyl-N-(2-morpholinoetliyl)pyrazol-4-amine trifluoroacetate. To a solution of 1 -methylpyrazol-4-amine (400 mg, 4.12 mmol) in DMF (10 ml) was added 4-(2- chloroethyl)morpholine (616 mg, 4.12 mmol), Cs<sub>2</sub>C0<sub>3</sub> (2.01 g, 6.18 mmol) and KI (684 mg, 4.12 mmol). The RM was stirred at 100 \u00b0C for 12 h then the solvent was removed under reduced pressure. The residue was purified by prep-HPLC (column: Phenomenex Luna C18 10 pm 250x50 mm; mobile phase: [water (0.1 % TFA) - ACN]; B: 0 - 4 %, 20 min) to give the title compound as a brown oil (Y = 13 %). 'H NMR (400 MHz, methanol-i/<sub>4</sub>) d ppm 7.30 (s, 1H),</p>7.21 (s, 1H), 3.95 - 3.90 (m, 4H), 3.80 (s, 3H), 3.40 - 3.33 (m, 8H). </p> [0936] Step 2: 3-(l,2,3,5,6,7-hexahydro-s-mdacen-4-yl)-l-[(l-methyI-lH-pyrazol-4-yl)[2- (morpholin-4-yl)ethyl] sulfamoyl] urea sodium salt. General procedure B was followed using</p>{[(l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoy!]amino}suifonyl chloride and l-methyl-N-(2- morpholinoethyl)pyrazol-4-amine trifluoroacetate. The crude product was purified by prep- HPLC (column: Agela Durashell 10 pm 250x50 mm; mobile phase: [water (10 mM NH<sub>4</sub>HCO<sub>3</sub>) - \n\n ACN]; B: 2 - 32 %, 20 min) to give the title compound as a white solid (Y = 7 %). <sup>!</sup>H NMR</p>(400 MHz, methanol-\u03ce) d ppm 7.74 (s, 1H), 7.55 (s, 1H), 6.95 (s, 1H), 3.99 - 3.92 (m, 2H), 3.92</p>- 3.83 (m, 7H), 3.27 - 3.20 (hr. s, 4H), 3.12 - 3.06 (m, 2H), 2.88 (t, J = 7 Hz, 4H), 2.82 (t, J= 7 Hz, 4H), 2.14 - 2.02 (m, 4H). LC-MS (ESI): m/z: [M+H]<sup>+</sup> - 489.2 </p>Example 47. 3-(l,2,3,5,6,7-hexahydro-s-indacen-4-yl)-l-[(l-methyl-lH-pyrazol-4-yl)(l- methyl-2-oxopiperidin-4-yl)sulfamoyl]urea sodium salt </p></p> [0937] Step 1: l-methyl-4-[(l-methylpyraz",
    "MR (400 MHz, DMSO- ) d ppm 9.41 (s, 1H), 7.20 (s, 1H), 7.04 (s, 1H), 3.71 (s, 3H), 3.52 - 3.34 (m, 2H), 3.24 - 3.00 (m, 4H), 2.81 - 2.69 (m, 1H), 2.02 - 1.89 (m, 2H), 1.77 - 1.65 (m, 2H), 1.32 - 1.18 (m, 4H). </p> [0990] Step 6: l-[(l-ethylpiperidm-3-yI)(l-methyI-lH-pyrazoI-4-yI)sulfamoyl]-3- (l,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea sodium salt. General procedure B was followed using {[(l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]amino}sulfonyl chloride and 1 -ethyl - N-( 1 -methylpyrazol-4-yl)piperidin-3 -amine trifluoroacetate. The crude product was purified by prep-HPLC (column: Xtimate C18 10 pm 250x50 mm; mobile phase: [water (10 mM </p>NH4HCO3) - ACN]; B: 1 - 33 %, 25 min) to give the title compound as an off-white solid (Y =</p>10 %). 'H NMR (400 MHz, methanol-A) d ppm 7.67 (s, 1H), 7.44 (s, 1H), 6.94 (s, 1H), 4.41 - 4.33 (m, 1H), 3.87 (s, 3H), 3.67 - 3.59 (m, 1H), 3.23 - 3.15 (m, 1H), 2.93 - 2.78 (m, 10H), 2.52 - 2.25 (m, 2H), 2.12 - 1.98 (m, 5H), 1.94 - 1.85 (m, 1H), 1.83 - 1.69 (m, 1H), 1.31 - 1.18 (m, 4H). LC-MS (ESI): m/z: [M+H]<sup>+</sup> = 487.2 \n\n Example 63. l-{[2-(azetidin-l-yl)ethyl](l-methyl-lH-pyrazol-4-yl)sulfamoyl}-3-(l,2,3,5,6,7- hexahydro-s-indacen-4-yl)urea sodium salt </p></p> [0991] Step 1: N-[2-(azetidm-l-yl)ethyl]-l-methyl-pyrazol-4-amine trifluoroacetate. To a solution of 1 -methylpyrazol-4-amine (406 mg, 4.18 mmol) in DMF (2 ml) was added l-(2- chloroethyl)azetidine (500 mg, 4.18 mmol), Cs<sub>2</sub>C0<sub>3</sub> (2.04 g, 6.27 mmol) and KI (763 mg, 4.60 mmol). The RM was stirred at 100 \u00b0C for 12 h. The solvent was removed under reduced pressure. The residue was purified by prep-HPLC (column: Phenomenex Luna C18 10 pm 250x50 mm; mobile phase: [water (0.1 % TFA) - ACN]; B: 0 - 5 %, 20 min) to give the title compound as a colourless oil. \u00be NMR (400 MHz, methanol-^) d ppm 7.20 (s, 1H), 7.13 (s, 1H), 4.29 - 4.02 (m, 4H), 3.78 (s, 3H), 3.37 - 3.33 (m, 2H), 3.21 - 3.13 (m, 2H), 2.69 - 2.34 (m, 2H). </p> [0992] Step 2: l-{[2-(azetidm-l-yl)ethyl](l-methyl-lH-pyrazol-4-yl)sulfamoyI}-3- (l,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea sodium salt. General procedure B was followed using {[(l,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]amino}sulfonyl chloride and N-[2- (azetidin- 1 -yl)ethyl]- 1 -methyl -pyrazol-4-amine trifluoroacetate. The crude product was purified by prep-HPLC (column: YMC-Triart prep Cl8-s 250x50 mm; mobile phase: [water (10 mM NH4HCO<sub>3</sub>) - ACN]; B: 1 - 31 %, 20 min) to give the title compound as a white solid (Y = 5 %). 'H NMR (400 MHz, methanol-^) d ppm 7.67 (s, 1H), 7.50 (s, 1H), 6.92 (s, 1H), 4.27 - 4.06 (m, 4H), 3.85 (s, 3H), 3.81 - 3.75 (m, 2H), 3.28 - 3.22 (m, 2H), 2.86 (t, /= 7 Hz, 4H), 2.80 (t, J= 1 Hz, 4H), 2.53 - 2.40 (m, 2H), 2.12 - 2.01 (m, 4H). LC-MS (ESI): m/z: [M+H]<sup>+</sup> = 459.2 </p>Example 64. 3-(l,2,3,5,6,7-hexahydro-s-indacen-4-yl)-l-[(l-methyl-lH-pyrazol-4-yl)[l- (propan-2-yl)azetidin-3-yl] sulfamoyl] urea sodium salt \n\n \n\n </p> [0993] Step 1: tert-butyl 3-[(l-methylpy",
    "e signal was developed after addition of 3 ,3\u2019 ,5,5\u2019 -tetramethylbenzidine-peroxidase (TMB) until colour appeared and the reaction was stopped by 2 M H2SO4. A microplate spectrophotometer (BioTek) was used to detect signals with 450 nm. The detection range of IL-lp ELISA was 2-150 ng/ml. Protocol B \n\n [01159] PBMC were isolated from buffy coats by density gradient centrifugation on Histopaque- 1077 (Sigma, cat no. 10771). Isolated cells were seeded into the wells (280,000 cells/well) of a 96-well plate and incubated for 3 h with lipopolysaccharide (LPS, 1 pg/ml diluted lOOOx from a 1 mg/ml stock solution). The compounds of the present disclosure were added (a single compound per well) and the cells were incubated for 30 min. Next, the cells were stimulated with ATP (5 mM final concentration diluted 20x from a 100 mM stock solution) for 1 h and the cell culture media from the wells were collected for further analysis. </p> [01160] The release of IL- 1 b into the media was determined by quantitative detection of IL- 1 b in the media using HTRF\u00ae, CisBio cat. No. 62HIL1BPEH. Briefly, cell culture supernatant were dispensed directly into the assay plate containing antibodies labelled with the HTRF\u00ae donor and acceptor. A microplate spectrophotometer (BMG) was used to detect signals at 655 nm and 620 nm. The detection range of IL-l b HTRF\u00ae was 39-6500 pg/ml. </p>[01161] The determination of the IC<sub>50</sub> values was preformed using the Graph Pad Prism software and the measured IC50 values of compounds of the present disclosure are shown in Table A below (\u201c++++\u201d means &lt;1 mM; \u201c+++\u201d means &gt;1 and &lt;3 mM; \u201c++\u201d means &gt;3 and &lt;10 mM; \u201c+\u201d means &gt;10 and &lt;50 mM). These results show that the compounds of the present disclosure are capable of inhibiting IL- 1 b release upon inflammasome activation. </p> Table A </p></p></p>302 \n\n\n\n \n\n</p></p>EQUIVALENTS </p> [01162] The details of one or more embodiments of the disclosure are set forth in the </p>accompanying description above. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. Other features, objects, and advantages of the disclosure will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms include plural referents unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents and publications cited in this specification are incorporated by reference. </p> [01163] The foregoing description has been presented only for the purposes of illustration and is not intended to limit the disclosure to the precise form disclosed, but by the claims appended hereto. \n</p>"
]